Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab
Allergy & Rhinology · 2018
DOI: 10.1177/2152656718763387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy & Rhinology, 2018. Verfasst von Abhishek Kavati und 8 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Indication of omalizumab in the United States was recently extended to include pediatric (6–11 years) uncontrolled moderate-to-severe allergic asthma patients.
Objective
The purpose of this study was to describe baseline characteristics of this population from a real-world dataset.
Methods
Allergic asthma patients and uncontrolled moderate-to-severe allergic asthma patients, aged 6–11 years, were identified in the Allergy Partners Network Electronic Medical Records (2007–2016). The index date for allergic asthma patients was the latest between the second asthma-related visit and the allergic status confirmation. Uncontrolled moderate-to-severe allergic asthma patients were stratified into omalizumab-exposed (index date) or omalizumab-unexposed (index date randomly generated) groups. Characteristics were evaluated during the 12-month preindex period.
Results
A total of 5806 allergic asthma, 37 omalizumab-exposed, and 2620 omalizumab-unexposed patients were selected (mean age approximately 9 years). Allergic asthma and omalizumab-unexposed patients were predominantly white (70.2% and 61.2%) whereas the majority of omalizumab-exposed were African Americans (62.2%). Mean immunoglobulin E was 782.0 IU/ml in allergic asthma patients (available in 2.2%), 1134.4 IU/ml in omalizumab-exposed (available in 100.0%), and 746.1 IU/ml in omalizumab-unexposed (available in 3.1%). Allergic asthma patients were less severe than omalizumab-exposed and omalizumab-unexposed based on the forced expiratory volume in 1 s as a percentage of predicted value (FEV 1 % predicted) and the Childhood Asthma Control Test (C-ACT). FEV 1 % predicted was below normal (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
- Analysis Group Inc., Montreal, QC, Canada.
- Allergy Partners P.A., Asheville, NC, USA.
Zitieren
APA
Kavati, A., Pilon, D., Ortiz, B., Paknis, B., Vegesna, A., Schiffman, B., Zhdanava, M., Lefebvre, P., & Stone, B. (2018). Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab. Allergy & Rhinology. https://doi.org/10.1177/2152656718763387
Vancouver
Kavati A, Pilon D, Ortiz B, Paknis B, Vegesna A, Schiffman B, et al. Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab. Allergy & Rhinology. 2018. doi:10.1177/2152656718763387
BibTeX
@article{Kavati2018,
author = {Kavati, Abhishek and Pilon, Dominic and Ortiz, Benjamin and Paknis, Brandee and Vegesna, Ashok and Schiffman, Bradd and Zhdanava, Maryia and Lefebvre, Patrick and Stone, Brian},
title = {Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab},
journal = {Allergy & Rhinology},
year = {2018},
doi = {10.1177/2152656718763387}
}
EUVIMED